These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 25993185)

  • 41. Practical guide to the use of radium 223 dichloride.
    Den RB; Doyle LA; Knudsen KE
    Can J Urol; 2014 Apr; 21(2 Supp 1):70-6. PubMed ID: 24775727
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
    Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H
    Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical response to radium-223 dichloride in men with metastatic castrate-resistant prostate cancer.
    Zhang I; Gilbo P; Kohn N; Cox B
    Pract Radiat Oncol; 2018; 8(6):452-457. PubMed ID: 29934137
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Alpha emitter radium-223 dichloride: new therapy in castration-resistant prostate cancer with symptomatic bone metastases].
    Heinzer H; König F; Klutmann S
    Urologe A; 2014 Apr; 53(4):519-23. PubMed ID: 24604017
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer.
    Nilsson S
    Curr Oncol Rep; 2016 Feb; 18(2):14. PubMed ID: 26779616
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dosing, administration, and safety of radium-223: How I do it.
    Dan TD; Doyle L; Raval AJ; Pridjian A; Gomella LG; Den RB
    Can J Urol; 2016 Jun; 23(3):8301-5. PubMed ID: 27347625
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chemotherapy following radium-223 dichloride treatment in ALSYMPCA.
    Sartor O; Hoskin P; Coleman RE; Nilsson S; Vogelzang NJ; Petrenciuc O; Staudacher K; Thuresson M; Parker C
    Prostate; 2016 Jul; 76(10):905-16. PubMed ID: 27004570
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancer.
    Dreicer R
    Clin Adv Hematol Oncol; 2015 May; 13(5):293-5. PubMed ID: 26352772
    [No Abstract]   [Full Text] [Related]  

  • 49. When to initiate treatment with radium-223 in patients with metastatic castration-resistant prostate cancer.
    Shore ND
    Clin Adv Hematol Oncol; 2016 Jan; 14(1):26-9. PubMed ID: 27057663
    [No Abstract]   [Full Text] [Related]  

  • 50. [Radium 223 in castration resistant prostate cancer.].
    Loizaga-Iriarte A; Camargo Ibargarai I; Senarriaga-Ruiz de la Illa N; Lacasa-Viscasillas I; Unda-Urzaiz M
    Arch Esp Urol; 2018 Sep; 71(8):696-703. PubMed ID: 30319129
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Updates on radium-223 for castration-resistant prostate cancer presented at the Genitourinary Cancers Symposium, January 7-9, 2016, San Francisco, California.
    Barkin J
    Can J Urol; 2016 Jun; 23(3):8306-7. PubMed ID: 27347626
    [No Abstract]   [Full Text] [Related]  

  • 52. Radium-223 for the treatment of metastatic castration-resistant prostate cancer: A window of opportunity.
    Gómez-Veiga F; Álvarez-Ossorio JL; Carballido-Rodríguez J; Juárez-Soto A; Rodríguez-Antolín A; Cozar-Olmo JM
    Actas Urol Esp (Engl Ed); 2018 Dec; 42(10):616-624. PubMed ID: 30041891
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Patient Selection for Radium-223 Therapy in Patients With Bone Metastatic Castration-Resistant Prostate Cancer: New Recommendations and Future Perspectives.
    van der Doelen MJ; Mehra N; Hermsen R; Janssen MJR; Gerritsen WR; van Oort IM
    Clin Genitourin Cancer; 2019 Apr; 17(2):79-87. PubMed ID: 30558834
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report.
    McNamara MA; George DJ
    BMC Cancer; 2015 May; 15():371. PubMed ID: 25948240
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prostate cancer - Therapy with radium-223.
    Brito AE; Amorim BJ; Martello M; Bernardo WM; Etchebehere E;
    Rev Assoc Med Bras (1992); 2017 Dec; 63(12):1019-1023. PubMed ID: 29489974
    [No Abstract]   [Full Text] [Related]  

  • 56. Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer.
    McNamara MA; Oyekunle T; Chin BB; Oldan J; Anand A; Ritz M; Shantzer L; Anand M; Armstrong AJ; George DJ
    Prostate; 2019 Jul; 79(10):1106-1116. PubMed ID: 31045266
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Radium-223 dichloride in clinical practice: a review.
    Florimonte L; Dellavedova L; Maffioli LS
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1896-909. PubMed ID: 27121689
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Radium-223 chloride: Extending life in prostate cancer patients by treating bone metastases.
    Wissing MD; van Leeuwen FW; van der Pluijm G; Gelderblom H
    Clin Cancer Res; 2013 Nov; 19(21):5822-7. PubMed ID: 24052017
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer.
    Carles J; Castellano D; Méndez-Vidal MJ; Mellado B; Saez MI; González Del Alba A; Perez-Gracia JL; Jimenez J; Suárez C; Sepúlveda JM; Manneh R; Porras I; López C; Morales-Barrera R; Arranz JÁ
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1133-e1139. PubMed ID: 30104161
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated?
    Serretta V; Valerio MR; Costa R; Tripoli V; Murabito A; Princiotta A; Scalici Gesolfo C; Borsellino N; Verderame F; Gebbia V; Licari M; Sanfilippo C;
    Urol Oncol; 2019 Dec; 37(12):964-969. PubMed ID: 31601517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.